Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06291324 · ClinicalTrials.gov registry record

WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment

A clinical trial of Breast Cancer and Pancreatic Cancer, sponsored by Wake Forest University Health Sciences.

Recruiting
Registry status
46
Enrollment target
1
Study location

NCT06291324: Recruiting study of Breast Cancer and Pancreatic Cancer, sponsored by Wake Forest University Health Sciences.

NCT06291324 is a study of Breast Cancer and Pancreatic Cancer that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 46 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06291324, a study of Breast Cancer and Pancreatic Cancer, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.

RECRUITING
Registry status
46 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the feasibility of using a commercial WATD (Wearable Activity Tracker Device) to collect HRV (Heart Rate Variability) data from pancreatic and breast cancer patients.

Primary Outcome

Adherence is a binary variable and will be determined based on whether the participant uploads HRV data each morning at least 75% of the days during the 14-day trial. Acceptability is a binary variable, and it is based on participant's response to the question whether they find the Wearable Activity Tracker Device (WATD) easy to use in the acceptability survey.

Conditions Studied

Breast Cancer Pancreatic Cancer

Study Locations (1)

North Carolina

  • Levine Cancer Institute - Charlotte

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2024-10-04
Est. Completion 2027-06-30
Wake Forest University Health Sciences

1,140 total trials

What NCT06291324 shows while recruiting

NCT06291324 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT06291324 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT06291324 about?

NCT06291324 is a clinical study titled "WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment". The purpose of this study is to evaluate the feasibility of using a commercial WATD (Wearable Activity Tracker Device) to collect HRV (Heart Rate Variability) data from pancreatic and breast cancer patients.

What is the current status of trial NCT06291324?

This trial is currently recruiting. The enrollment target is 46 participants. The study started on 2024-10-04. Estimated completion is 2027-06-30.

What conditions does trial NCT06291324 study?

This clinical trial studies the following conditions: Breast Cancer, Pancreatic Cancer.

Who is sponsoring clinical trial NCT06291324?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06291324 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06291324's enrollment target sits among peer trials

46 835th of 1224 higher than 383 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01890590 · 46 participants · NA

    A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

  • NCT03191149 · 46 participants · Phase 2

    Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • NCT03510208 · 46 participants · Phase 1

    Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

  • NCT04048278 · 46 participants · Early Phase 1

    Lidocaine Infusion in Pancreatic Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06291324

Source: ClinicalTrials.gov NCT06291324, the US trial registry maintained by the National Library of Medicine. NCT06291324 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.